[go: up one dir, main page]

AR059452A1 - A NON-IONIC SOLVENT, A STABILIZED PHARMACEUTICAL COMPOSITION THAT INCLUDES A TAXAN AND A PROCESS FOR THE PREPARATION OF THE NON-IONIC SOLVENT - Google Patents

A NON-IONIC SOLVENT, A STABILIZED PHARMACEUTICAL COMPOSITION THAT INCLUDES A TAXAN AND A PROCESS FOR THE PREPARATION OF THE NON-IONIC SOLVENT

Info

Publication number
AR059452A1
AR059452A1 ARP070100637A ARP070100637A AR059452A1 AR 059452 A1 AR059452 A1 AR 059452A1 AR P070100637 A ARP070100637 A AR P070100637A AR P070100637 A ARP070100637 A AR P070100637A AR 059452 A1 AR059452 A1 AR 059452A1
Authority
AR
Argentina
Prior art keywords
ionic solvent
pharmaceutical composition
taxan
preparation
stabilized pharmaceutical
Prior art date
Application number
ARP070100637A
Other languages
Spanish (es)
Inventor
Dinesh Kumar
Santosh Kumar Deolia
Rajeev Kumar Yadav
Rajesh Singh Tomar
Original Assignee
Dabur Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dabur Pharma Ltd filed Critical Dabur Pharma Ltd
Publication of AR059452A1 publication Critical patent/AR059452A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Un solvente no ionico que tiene un valor de conductividad menor o igual a 5,0 micro-semens, que es capaz de proporcionar una composicion farmacéutica estabilizada que comprende un taxano. Una composicion farmacéutica estable de taxanos y un método para prepararla.A non-ionic solvent having a conductivity value less than or equal to 5.0 micro-semesters, which is capable of providing a stabilized pharmaceutical composition comprising a taxane. A stable pharmaceutical composition of taxanes and a method to prepare it.

ARP070100637A 2006-02-21 2007-02-14 A NON-IONIC SOLVENT, A STABILIZED PHARMACEUTICAL COMPOSITION THAT INCLUDES A TAXAN AND A PROCESS FOR THE PREPARATION OF THE NON-IONIC SOLVENT AR059452A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN473DE2006 2006-02-21

Publications (1)

Publication Number Publication Date
AR059452A1 true AR059452A1 (en) 2008-04-09

Family

ID=38191277

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100637A AR059452A1 (en) 2006-02-21 2007-02-14 A NON-IONIC SOLVENT, A STABILIZED PHARMACEUTICAL COMPOSITION THAT INCLUDES A TAXAN AND A PROCESS FOR THE PREPARATION OF THE NON-IONIC SOLVENT

Country Status (5)

Country Link
EP (1) EP1998808A1 (en)
AR (1) AR059452A1 (en)
AU (1) AU2007219104B2 (en)
CA (1) CA2642324C (en)
WO (1) WO2007096900A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615292A8 (en) 2005-08-31 2018-03-06 Abraxis Bioscience Llc compositions and methods for preparing poorly soluble water drugs with increased stability
SI3311805T1 (en) 2005-08-31 2020-07-31 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
AU2011248449B2 (en) 2010-05-03 2016-09-15 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
JO3685B1 (en) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc Non-aqueous taxane nanodispersion formulations and methods of using the same
CN107929750B (en) * 2017-12-20 2021-06-08 江苏九旭药业有限公司 Anti-tumor pharmaceutical composition and preparation method and application thereof
CN116328361A (en) * 2023-03-23 2023-06-27 四川汇宇制药股份有限公司 Stable paclitaxel solution and its preparation method and use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2561330A (en) * 1948-03-25 1951-07-24 Phillips Petroleum Co Process for refining soybean oil
FR2601675B1 (en) 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
US6388112B1 (en) * 1998-10-20 2002-05-14 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceutical compositions
EP1624896B1 (en) * 2003-05-19 2009-07-29 Ebewe Pharma Ges.m.b.H. Nfg. KG Method for the production of a stable injectable formulation made of paclitaxel
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
EP1690551A3 (en) * 2005-02-10 2006-10-18 Sindan Pharma Srl Method of purifying a surfactant by ultrafiltration

Also Published As

Publication number Publication date
AU2007219104A1 (en) 2007-08-30
AU2007219104B2 (en) 2010-07-01
EP1998808A1 (en) 2008-12-10
WO2007096900A1 (en) 2007-08-30
CA2642324C (en) 2011-03-29
CA2642324A1 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
UY33397A (en) SOLID FORM OF A CARBOXAMIDE NAFTALEN
UY32388A (en) SOLID PHARMACEUTICAL COMPOSITION THAT INCLUDES AMLODIPINE AND LOSARTAN WITH IMPROVED STABILITY
CL2011000527A1 (en) Compounds derived from benzofuran; pharmaceutical composition that includes them; and their use in the treatment of hepatitis c.
CL2007001838A1 (en) COMPOUNDS DERIVED FROM 4-OXOQUINOLINE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE PRODUCTION OF AN ANTI-HIV AGENT.
NI201001032A (en) CRSITALINE FORMS OF DIMETOXI DOCETAXEL AND METHOD TO PREPARE THE SAME.
CL2008002269A1 (en) Composition useful for treating plants, comprising an oily medium containing 1-methyl-cyclopropene particles encapsulated by an encapsulating agent, said particles being 50 microns or less and where the oily medium also comprises one or more dispersant.
CL2007003540A1 (en) COMPOUNDS DERIVED FROM MACROCICLES, INHIBITORS OF THE SERINE PROTEASE OF HEPATITIS C; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF HEPATITIS C.
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
UY30711A1 (en) NEW DERIVATIVES OF 1,4-BENZOTIEPINA-1, 1-CIOXIDE, METHOD FOR PREPARATION, PHARMACEUTICAL PRODUCTS THAT INCLUDE THESE COMPOUNDS AND THEIR USE.-
CL2012001722A1 (en) Compounds derived from 3-hydroxy-5-arylisothiazole, agonists of receptor 40 coupled to protein g (gpr40); pharmaceutical composition comprising them; and method for the treatment or prevention of diabetes.
CL2007002971A1 (en) COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS.
MX2024009207A (en) IMPROVEMENT IN OR WITH RELATION TO ORGANIC COMPOUNDS
CL2007001869A1 (en) COMPOUNDS DERIVED FROM BENCIMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITIONS; AND USE FOR THE TREATMENT AND / OR PROFILAXIS OF DISEASES MODULATED WITH FXR AGONISTS, SUCH AS DISLIPIDEMIAS, DIABETES, CANCER, OSTEOPOROSIS AND E
CL2008002295A1 (en) Alkylsulfonyl-substituted thiazolid derivative compounds; pharmaceutical composition; and use for the treatment of hepatitis c.
CL2008002162A1 (en) Compounds derived from 3-benzoisoxazole-piperidine; pharmaceutical composition comprising said compounds; and its use for the treatment and / or prevention of cognitive disorders, drug addiction, depression, anxiety, among others.
CL2007003722A1 (en) COMPOUNDS DERIVED FROM PROPIONAMIDE N-REPLACED BY HETEROCICLO, GLUCOQUINASA ACTIVATORS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OR PREVENTION OF DIABETES.
CL2009000309A1 (en) Aromatic fluoroglycoside derivatives, pharmaceutical composition containing these compounds, procedure to prepare it and its use in the treatment of type 1 and type 2 diabetes.
DOP2016000253A (en) NEW COMPOUNDS
BRPI0713031B8 (en) dihydro-pyran-2-one compound, pharmaceutical composition, and use thereof
AR059452A1 (en) A NON-IONIC SOLVENT, A STABILIZED PHARMACEUTICAL COMPOSITION THAT INCLUDES A TAXAN AND A PROCESS FOR THE PREPARATION OF THE NON-IONIC SOLVENT
SV2011003852A (en) INHALABLE PARTICLES THAT INCLUDE TIOTROPIO
CL2007002479A1 (en) COMPOUNDS DERIVED FROM PIRAZOL; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS.
BRPI0717369A2 (en) COMPOUND, MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
CL2007002862A1 (en) USE OF THE EPIDERMIC GROWTH FACTOR (EGF) TO TREAT SENSITIVE-MOTOR, PAINFUL NEUROPATHY AND MANIFESTATIONS OF ISCHEMICAL NEURITIS; PHARMACEUTICAL COMPOSITION INCLUDED BY EGF; AND USE OF THE COMPOSITION BEFORE SUCH.
CL2013003111A1 (en) Method for the preparation of a pharmaceutical composition containing a purified and thermally stable oxygen transporter, which contains the hemoglobin oxygen transporter, where hemoglobin includes crosslinked polymeric hemoglobin.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal